| General Information | |
|---|---|
| ZINC ID | ZINC000043062339 |
| Molecular Weight (Da) | 604 |
| SMILES | Cc1nc(NCc2ccc(C(F)(F)F)cc2)cc(N[C@@H](C)[C@@H](Cc2ccc(Cl)cc2)c2cccc(Br)c2)n1 |
| Molecular Formula | C29Br1Cl1F3N4 |
| Action | Antagonist |
| Physicochemical Details | |
|---|---|
| Molar Refractivity | 152.302 |
| HBA | 2 |
| HBD | 2 |
| Rotatable Bonds | 10 |
| Heavy Atoms | 38 |
| LogP | 8.736 |
| Activity (Ki) in nM | 158.489 |
| Polar Surface Area (PSA) | 49.84 |
| Pharmacokinetic Properties (AdmetSAR) | |
|---|---|
| Human intestinal absorption | + |
| Caco-2 | - |
| Blood brain barrier | + |
| P-glycoprotein inhibitior | + |
| P-glycoprotein substrate | - |
| Cyp3a4 substrate | + |
| Cyp2c9 substrate | - |
| Cyp2d6 substrate | - |
| Cyp3a4 inhibition | + |
| Cyp2c9 inhibition | - |
| Cyp2c19 inhibition | + |
| Cyp2d6 inhibition | - |
| Cyp1a2 inhibition | + |
| Acute oral toxicity | - |
| Carcinogenicity (binary) | - |
| Ames mutagenesis | - |
| Human ether-a-go-go-related gene inhibition | + |
| Biodegradation | - |
| Glucocorticoid receptor binding | + |
| Thyroid receptor binding | + |
| Androgen receptor binding | + |
| Plasma protein binding | 1.10658013 |
| Pharmacokinetic Properties (SwissADME) | |
|---|---|
| Number of aromatic heavy atoms | 24 |
| Fraction csp3 | 0.24 |
| Ilogp | 5.04 |
| Xlogp3 | 9.07 |
| Wlogp | 9.28 |
| Mlogp | 6.07 |
| Silicos-it log p | 8.34 |
| Consensus log p | 7.56 |
| Esol log s | -9.11 |
| Esol solubility (mg/ml) | 0.00000047 |
| Esol solubility (mol/l) | 7.84E-10 |
| Esol class | Poorly sol |
| Ali log s | -10.01 |
| Ali solubility (mg/ml) | 0.00000005 |
| Ali solubility (mol/l) | 9.78E-11 |
| Ali class | Insoluble |
| Silicos-it logsw | -13.04 |
| Silicos-it solubility (mg/ml) | 5.57E-11 |
| Silicos-it solubility (mol/l) | 9.23E-14 |
| Silicos-it class | Insoluble |
| Pgp substrate | |
| Log kp (cm/s) | -3.54 |
| Lipinski number of violations | 2 |
| Ghose number of violations | 3 |
| Veber number of violations | 0 |
| Egan number of violations | 1 |
| Muegge number of violations | 2 |
| Bioavailability score | 0.17 |
| Pains number of alerts | 0 |
| Brenk number of alerts | 0 |
| Leadlikeness number of violations | 3 |
| Synthetic accessibility | 4.3 |
| Pharmacokinetic Properties (ADMETLab) | |
|---|---|
| Logs | -6.83 |
| Logd | 4.931 |
| Logp | 7.675 |
| F (20%) | 0.003 |
| F (30%) | 0.002 |
| Mdck | - |
| Ppb | 99.85% |
| Vdss | 4.002 |
| Fu | 0.96% |
| Cyp1a2-inh | 0.729 |
| Cyp1a2-sub | 0.814 |
| Cyp2c19-inh | 0.874 |
| Cyp2c19-sub | 0.049 |
| Cl | 3.783 |
| T12 | 0.006 |
| H-ht | 0.527 |
| Dili | 0.417 |
| Roa | 0.666 |
| Fdamdd | 0.932 |
| Skinsen | 0.015 |
| Ec | 0.003 |
| Ei | 0.01 |
| Respiratory | 0.855 |
| Bcf | 2.509 |
| Igc50 | 5.169 |
| Lc50 | 6.583 |
| Lc50dm | 7.059 |
| Nr-ar | 0.063 |
| Nr-ar-lbd | 0.004 |
| Nr-ahr | 0.5 |
| Nr-aromatase | 0.577 |
| Nr-er | 0.555 |
| Nr-er-lbd | 0.014 |
| Nr-ppar-gamma | 0.005 |
| Sr-are | 0.673 |
| Sr-atad5 | 0.059 |
| Sr-hse | 0.046 |
| Sr-mmp | 0.752 |
| Sr-p53 | 0.288 |
| Vol | 540.961 |
| Dense | 1.113 |
| Flex | 0.36 |
| Nstereo | 2 |
| Nongenotoxic carcinogenicity | 1 |
| Ld50 oral | 0 |
| Genotoxic carcinogenicity mutagenicity | 1 |
| Surechembl | 0 |
| Nonbiodegradable | 2 |
| Skin sensitization | 2 |
| Acute aquatic toxicity | - |
| Toxicophores | 0 |
| Qed | 0.214 |
| Synth | 3.811 |
| Fsp3 | 0.241 |
| Mce-18 | 52 |
| Natural product-likeness | -0.945 |
| Alarm nmr | 2 |
| Bms | 0 |
| Chelating | 0 |
| Pfizer | - |
| Gsk | Rejected |
| Goldentriangle | Rejected |